Avila Appoints Andrew Hirsch as CFO

Avila Therapeutics, a biotechnology company, has appointed Andrew Hirsch as its first chief financial officer (CFO). Hirsch joins Avila from Biogen Idec where he spent the past 10 years in a number of roles of increasing responsibility – most recently as vice president of corporate strategy and merger and acquisition (M&A).

Hirsch’s prior roles during his tenure at Biogen Idec included responsibilities in the finance organisation for corporate planning, budget development and management, and investor relations.

Hirsch led business development for a software start-up company and spent several years in management consulting at Stern Stewart & Co and The Parthenon Group. He graduated from the University of Pennsylvania with a BA in Economics and holds a MBA from The Tuck School at Dartmouth College.


Related reading